Ariad Pharmaceutical Stock Rating Lowered by Oppenheimer (ARIA)

Oppenheimer lowered shares of Ariad Pharmaceutical (NASDAQ: ARIA) from an outperform rating to a perform rating in a research report released on Tuesday morning. Oppenheimer currently has $23.00 price target on the stock, up from their previous price …

Share